MDCalc

Bova Score for Pulmonary Embolism Complications

Predicts 30-day risk of PE-related complications in hemodynamically stable patients.

Use ONLY in hemodynamically stable patients (sBP ≥90) with confirmed acute PE (pulmonary embolism).

Systolic BP
If sBP <90, patient not eligible for Bova scoring
Elevated cardiac troponin
Standard assay and lab cutoff value
RV dysfunction
On TTE: RV/LV ratio >0.9, sPAP >30, RV end diastolic diameter >30mm, RV dilation, or free wall hypokinesis; on CT: RV/LV ratio >1 (short axis diameter)
Heart rate, beats/min

Result:

Please fill out required fields.
Advice
  • Risk of PE-related complications (death from PE, hemodynamic collapse, or recurrent nonfatal PE) increases in patients with higher Bova Score.
  • Consider assessing high-risk patients for advanced therapy in addition to anticoagulation (catheter-directed therapy, thrombolytic therapy, IVC filter placement) if warranted.
  • Consider monitoring patients with intermediate and high risk Bova Scores in a higher level of care (stepdown unit, ICU).
  • Consider standard treatment (anticoagulation alone) for patients with a low risk Bova Score.
Management
  • Optimal management of intermediate risk patients with acute PE is unclear, but escalation of care (e.g. thrombolysis, referral to ICU) should be considered in patients who are not low risk.
  • Consider multidisciplinary discussion regarding treatment options for patients with a high risk (>4) Bova Score.
Critical Actions
  • High risk patients (stage III) should be monitored closely and a plan for rescue therapy should be made in case of clinical deterioration.
  • Stage III patients may warrant multidisciplinary discussion regarding management.
  • Additional findings and pathology not included in the Bova Score should also be considered, such as respiratory rate, need for respiratory support, SpO₂, syncope, elevated lactic acid, coexisting DVT, and other underlying chronic comorbidities.
  • The Bova Score does not predict risks of therapy such as bleeding with thrombolytic therapy or anticoagulation.